Literature DB >> 24455762

Effects of hydrophilic statins on renal tubular lipid accumulation in diet-induced obese mice.

Koro Gotoh, Takayuki Masaki, Seiichi Chiba, Hisae Ando, Kansuke Fujiwara, Takanobu Shimasaki, Yasuko Tawara, Ikuko Toyooka, Kentaro Shiraishi, Kimihiko Mitsutomi, Manabu Anai, Emi Itateyama, Junji Hiraoka, Kohei Aoki, Naoya Fukunaga, Tomoko Nawata, Tetsuya Kakuma.   

Abstract

Animal models of obesity show that lipid deposits can injure the kidneys,and there is evidence for the role of lipids in the development of chronic renal dis-ease (CKD). Statins exhibit a lipid-lowering effect that acts on both total cholesterol and triglyceride (TG) levels and pleiotropic effects including their ability to reduce inflammation and fibrosis. The purpose of the present study was to confirm whether obesity induced by a high-fat diet (HFD, 60% fat) promotes lipid accumulation in the tubulointerstitial and/or glomerular areas in the kidney, and whether treatment of several statins, pravastatin (30 mg/kg, p.o.), rosuvastatin (3 mg/kg, p.o.),pitavastatin (1 mg/kg, p.o.) and atorvastatin (10 mg/kg, p.o.), suppresses obesity-induced lipid accumulation. Using male C57Bl/6J mice, we examined parameters related to energy metabolism, lipid accumulation as well as macrophage infiltration in glomeruli and the tubulointerstitial area, and glomerular injury using nephrin and desmin expression. None of the statins affected body weight, glucose metabolism,serum TG and adiponectin levels, or serum inflammatory cytokine levels. However,all statins improved lipid accumulation in the proximal tubules, improved glomerular hypertrophy, increased nephrin expression and decreased desmin expression, compared to non-treated obese animals. Moreover, the reduction of proximal tubular lipid accumulation was greater with pravastatin and rosuvastatin treatment than with pitavastatin and atorvastatin treatment. We concluded that hydrophilic statins may be more effective for preventing lipid accumulation in renal tubules than lipophilic statins.
© 2013 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24455762     DOI: 10.1016/j.orcp.2013.04.001

Source DB:  PubMed          Journal:  Obes Res Clin Pract        ISSN: 1871-403X            Impact factor:   2.288


  3 in total

1.  Renal protection by atorvastatin in a murine model of sickle cell nephropathy.

Authors:  Rima S Zahr; Prasanthi Chappa; Hong Yin; Lou A Brown; Kenneth I Ataga; David R Archer
Journal:  Br J Haematol       Date:  2018-03-12       Impact factor: 6.998

Review 2.  Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.

Authors:  Vivette D D'Agati; Avry Chagnac; Aiko P J de Vries; Moshe Levi; Esteban Porrini; Michal Herman-Edelstein; Manuel Praga
Journal:  Nat Rev Nephrol       Date:  2016-06-06       Impact factor: 28.314

3.  Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy.

Authors:  Kyeong Ho Yun; Jae Hong Lim; Kyo Bum Hwang; Sun Ho Woo; Jin Woo Jeong; Yong Cheol Kim; Dai-Yeol Joe; Jum Suk Ko; Sang Jae Rhee; Eun Mi Lee; Seok Kyu Oh
Journal:  Korean Circ J       Date:  2014-09-25       Impact factor: 3.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.